EN DE

Dr LASCOMBE Isabelle

Fiche personne

coordonnées

UFR Sciences Médicales et Pharmaceutiques
Laboratoire de Biologie Cellulaire et Moléculaire EA3181
19 Rue Ambroise Paré
25030 BESANÇON Cedex

03 63 08 22 28

isabelle.lascombe@univ-fcomte.fr

Territoire

Franche-Comté

Statut

Enseignant-Chercheur

affiliation

Centre hospitalier régional universitaire de Besançon (CHRU Besançon)

Université de Franche-Comté (UFC)

équipes/plateformes

Equipe EA 3181 - Equipe "Carcinogenèse associée aux HPV"

Recherche

Projets

Etude de l’effet d’une molécule pharmacologique, agoniste de PPARβ/δ, sur la régulation de la cadhérine N, un marqueur de progression tumorale, dans des cellules urothéliales malignes

2012 - Porteur du projet : Dr LASCOMBE Isabelle

Publications

Concomitant decrease of E- and A-FABP expression predicts worse survival in urothelial bladder cancer patients.

Saizonou I, Lascombe I, Monnien F, Bedgedjian I, Kleinclauss F, Algros MP, Fauconnet S

Sci Rep. 2024 07 4;14(1):15390

GW501516-Mediated Targeting of Tetraspanin 15 Regulates ADAM10-Dependent N-Cadherin Cleavage in Invasive Bladder Cancer Cells.

Barbaud A, Lascombe I, Péchery A, Arslan S, Kleinclauss F, Fauconnet S

Cells. 2024 04 19;13(8):

Molecular and nanoscale evaluation of N-cadherin expression in invasive bladder cancer cells under control conditions or GW501516 exposure.

Elie-Caille C, Lascombe I, Péchery A, Bittard H, Fauconnet S

Mol. Cell. Biochem.. 2020 Jun 9;:

Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up.

Mathis C, Lascombe I, Monnien F, Bittard H, Kleinclauss F, Bedgedjian I, Fauconnet S, Valmary-Degano S

BMC Cancer. 2018 Dec 10;18(1):1239

Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells.

Plissonnier ML, Fauconnet S, Bittard H, Mougin C, Rommelaere J, Lascombe I

Oncotarget. 2017 Dec 8;8(64):107744-107762

Apoptotic effect of the selective PPARβ/δ agonist GW501516 in invasive bladder cancer cells.

Péchery A, Fauconnet S, Bittard H, Lascombe I

Tumour Biol.. 2016 Nov;37(11):14789-14802

The PPARbeta agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism.

Roche E, Lascombe I, Bittard H, Mougin C, Fauconnet S

Cell Signal. 2014 Feb;26(2):433-43

The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL.

Plissonnier ML, Fauconnet S, Bittard H, Lascombe I

PLoS One. 2011;6(12):e28354

Insights on distinct pathways of thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cells.

Plissonnier ML, Fauconnet S, Bittard H, Lascombe I

Int J Cancer. 2010 Oct 15;127(8):1769-84.

Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.

Wallerand H, Cai Y, Wainberg ZA, Garraway I, Lascombe I, Nicolle G, Thiery JP, Bittard H, Radvanyi F, Reiter RR

Urol Oncol. 2010 Mar-Apr;28(2):180-8

Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer

Fauconnet S, Bernardini S, Lascombe I, Boiteux G, Clairotte A, Monnien F, Chabannes E, Bittard H

Oncol Rep. 2009 Jun;21(6):1495-504.

A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells.

Boiteux G, Lascombe I, Roche E, Plissonnier ML, Clairotte A, Bittard H, Fauconnet S

Int J Cancer. 2009 Apr 15;124(8):1820-8.

N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.

Lascombe I, Clairotte A, Fauconnet S, Bernardini S, Wallerand H, Kantelip B, Bittard H

Clin Cancer Res. 2006 May 1;12(9):2780-7.

Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors.

Clairotte A, Lascombe I, Fauconnet S, Mauny F, Felix S, Algros MP, Bittard H, Kantelip B

Am J Clin Pathol. 2006 Jan;125(1):119-26.

Angiogenesis and bladder cancer: role of vascular endothelial growth factor.

LASCOMBE I, FAUCONNET S, CHABANNES E, BITTARD H

In : Progress in Bladder Cancer Research. Pp. 19-65, vol 6, 2005.

Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells.

Fauconnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, Wahli W, Bittard H

J Biol Chem. 2002 Jun 28;277(26):23534-43